SciSparc Ltd. (SPRC)
| Market Cap | 4.08M +21.6% |
| Revenue (ttm) | 856,000 -34.5% |
| Net Income | -12.18M |
| EPS | -98.07 |
| Shares Out | 573.24K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,503 |
| Open | 7.57 |
| Previous Close | 8.70 |
| Day's Range | 6.61 - 8.00 |
| 52-Week Range | 2.98 - 80.10 |
| Beta | 2.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About SPRC
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral ta... [Read more]
Financial Performance
In 2025, SciSparc's revenue was $856,000, a decrease of -34.46% compared to the previous year's $1.31 million. Losses were -$12.18 million, 93.8% more than in 2024.
Financial StatementsNews
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
Scisparc Ltd trading halted, volatility trading pause
09:53 EDT Scisparc (SPRC)Ltd trading halted, volatility trading pause
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
SciSparc to target agentic artificial intelligence market
SciSparc (SPRC)announced that its board of directors has made a decision to target the agentic artificial intelligence market. As part of this initiative, the company has decided to establish a…
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artifi...
SciSparc initiates SCI-110 clinical trial in Germany
SciSparc (SPRC)announced that its subsidiary NeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary ca...
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clin...
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd...
NeuroThera Labs Announces Upsize to Private Placement
Toronto, ON – July 2, 2026 - TheNewswire – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasd...
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
Toronto, ON – TheNewswire - June 30, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nas...
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “ Company ” or “ NeuroThera ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd...
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar...
Neurothera Labs Announces Adoption of Semi-Annual Reporting
May 20, 2026 – TheNewswire - Toronto, Ontario, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSp...
Neurothera Labs Announces Continuance into Ontario
April 30, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidi...
Neurothera Labs Engages bullVestor for Investor Relations Activities
April 23, 2026 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsi...
SciSparc discloses patent application for depression yherapy
The company states: “SciSparc (SPRC)has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectua...
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
SciSparc’s Neurothera Labs announces publication of international patent
SciSparc (SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine (CMND) with the publication ...
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum
NeuroThera Labs, in which SciSparc (SPRC)holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement between NeuroThera, CliniQuantum and the Selling Shar...
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market ...
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.
Vancouver, British Columbia – March 10, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of ...